L’immunothérapie dans les cancers ORL

Abstract

Immunotherapy wave has also touched head and neck cancer. In recurrent or metastatic disease, checkpoint inhibitors (anti PD-1/PD-L1) are approved in 2^nd line with a clear benefit on overall survival and quality of life. Multiple clinical studies are in progress in both palliative and curative intent, combined or not with other checkpoint inhibitor (anti-CTLA4) or other standard therapies (radiotherapy, chemotherapy). It is essential to define which patients will benefit from immunotherapy, according to robust biomarkers, in order to increase risk benefit balance by decreasing side effects and selecting those who respond the most. Here we present an overview of immunotherapy in 2018 in head and neck squamous cell cancer.

Keywords: Biomarkers; Biomarqueurs; Carcinome; Checkpoint inhibitors; Clinical trials; Essais cliniques; Head and neck; Immunotherapy; Immunothérapie; Inhibiteurs de; carcinoma; checkpoint; et cou; squamous cell; épidermoïde tête.